Chief Legal and Strategy Officer and Secretary · TScan Therapeutics, Inc. (TCRX)

Zoran Zdraveski

FY2023 is the first fiscal year CompBrief holds for Zoran Zdraveski as a named executive officer of TScan Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,581,766

Salary $441,000Stock awards $0

4th of 5 named executive officers at TScan Therapeutics by FY2023 total.

5 named officers on file for TScan Therapeutics, FY2023

Zoran Zdraveski’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TScan Therapeutics’s whole pay program stands against its peers

  • TScan Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Zoran Zdraveski’s full pay file as a PDF — free

More than this page: up to 10 years of Zoran’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Zoran Zdraveski compensation by year

TScan Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as TScan Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$441,000
Bonus$0
Stock awards$0
Option awards$924,566
Non-equity incentive$203,000
Pension and deferred compensation$0
All other$13,200
Total$1,581,766

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TScan Therapeutics, Inc. DEF 14A filed April 30, 2024, accession 0001193125-24-125066, and prior-year filings. Open the filing on EDGAR.

How this page was built: the TScan Therapeutics, Inc. filed document, accession 0001193125-24-125066. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option43,379—$8.99
Option22,246—$6.16
Option42,500—$4.85
Option1,771—$4.85
Option7,294—$3.27
Option24,998—$3.27
Option10,209—$1.81
Option24,791—$1.81
Option42,363—$2.49
Option177,637—$2.49
Option64,797—$2.49
Option145,203—$2.49

Per the Outstanding Equity Awards at Fiscal Year-End table in TScan Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2023 proxy (filed April 30, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-10-01Grant or award—300,000$0.00304,716
2026-01-20Grant or award derivative—350,000$0.00350,000
2025-01-03Grant or award derivative—250,000$0.00250,000
2024-01-12Grant or award derivative—52,500$0.0052,500

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

TScan Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Gavin MacBeathChief Executive Officer and Director$3,196,054
Debora BartonFormer Chief Medical Officer$1,709,996
Brian SilverFormer Chief Financial Officer and Treasurer$1,584,172
Zoran Zdraveski · this pageChief Legal and Strategy Officer and Secretary$1,581,766
David SouthwellFormer President, Chief Executive Officer and Director$1,292,446

The full TScan Therapeutics compensation record

free company brief

This page is one person within TScan Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TScan Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Zoran Zdraveski's compensation dossier · One-time report. No refunds.